Table1_House dust mite sublingual allergen immunotherapy tablet is safe and well-tolerated in Dutch clinical practice.docx

Background Half (49%) of clinically diagnosed allergic rhinitis (AR) patients are sensitized to house dust mite (HDM). If allergen avoidance and symptomatic medication fail, allergen immunotherapy may be indicated. Objective We investigated safety and tolerability of HDM-sublingual immunotherapy by HDM-SLIT tablets in Dutch daily clinical practice. Methods Daily intake of 12 SQ-HDM SLIT-tablet was investigated in a prospective, multicenter, observational study (EUPAS43753). It comprised 4 consultations in 1 year. Data on safety, tolerability, treatment satisfaction, symptomatic medication, com... Mehr ...

Verfasser: Žana Tempels-Pavlica
Mark C. J. Aarts
Paco M. J. Welsing
Akke-Nynke van der Meer
Leonard P. van der Zwan
Elena Uss
André C. Knulst
Dokumenttyp: Dataset
Erscheinungsdatum: 2024
Schlagwörter: Medicine / Molecular Biology / Immunology / Allergy / Innate Immunity / allergic rhinitis / Control of Allergic Rhinitis and Asthma Test (CARAT) / house dust mite (HDM) / safety / sublingual immunotherapy tablet / non-interventional study / general medicine / outpatient clinic
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-26631572
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.3389/falgy.2024.1355324.s001